Key result
High-dose TGFβ receptor inhibitors paradoxically stimulate MEK-driven fibrotic ECM remodeling.
Why the study?
Models generating quantitative data on 3D fibroblast-mediated ECM remodeling with the reproducibility and throughput needed for drug testing were lacking.
Does inhibition of specific signaling pathways (e.g., MEK, ROCK, LOX) reduce TGFβ-induced 3D ECM remodeling in primary human fibroblasts?
Does inhibition of specific signaling pathways (e.g., MEK, ROCK, LOX) reduce TGFβ-induced 3D ECM remodeling in primary human fibroblasts?
A novel 3D high-throughput assay reveals that non-canonical MEK-ERK signaling drives fibrotic ECM remodeling and that high doses of TGFβ receptor inhibitors paradoxically stimulate this profibrotic activity.
Answers are grounded in this paper and cite their sources.
High-dose TGFβ inhibitors may paradoxically promote fibrosis; leaves open MEK-ERK targeting in cardiac fibrotic remodeling.
In fibrotic tissues, activated fibroblasts remodel the collagen-rich extracellular matrix (ECM). Intervening with this process represents a candidate therapeutic strategy to attenuate disease progression. Models that generate quantitative data on 3D fibroblast-mediated ECM remodeling with the reproducibility and throughput needed for drug testing are lacking. Here, we develop a model that fits this purpose and produces combined quantitative information on drug efficacy and cytotoxicity. We use microinjection robotics to design patterns of fibrillar collagen-embedded fibroblast clusters and apply automated microscopy and image analysis to quantify ECM remodeling between-, and cell viability within clusters of TGFβ-activated primary human skin or lung fibroblasts. We apply this assay to compound screening and reveal actionable targets to suppress fibrotic ECM remodeling. Strikingly, we find that after an initial phase of fibroblast activation by TGFβ, canonical TGFβ signaling is dispensable and, instead, non-canonical activation of MEK-ERK signaling drives ECM remodeling. Moreover, we reveal that higher concentrations of two TGFβ receptor inhibitors while blocking canonical TGFβ signaling, in fact stimulate this MEK-mediated profibrotic ECM remodeling activity.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2025) studied Fibrosis. MEK inhibitors and TGFβ receptor inhibitors vs. Control medium was evaluated on ECM remodeling between fibroblast clusters. Non-canonical activation of MEK-ERK signaling drives fibrotic ECM remodeling, and high concentrations of TGFβ receptor inhibitors paradoxically stimulate this MEK-mediated profibrotic activity.
Synapse has enriched 10 related papers. Consider them for comparative context: